OneStream, Inc.(OS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

OS OneStream, Inc.

Trading 02-04 10:45:01 EST

23.07

-0.28

-1.22%

High23.37	Low22.96	Vol5.12M
Open23.36	D1 Closing23.35	Amplitude1.76%
Mkt Cap5.65B	Tradable Cap5.09B	Total Shares244.98M
T/O118.76M	T/O Rate2.32%	Tradable Shares220.70M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"OS","market":"US","secType":"STK","nameCN":"OneStream, Inc.","latestPrice":23.065,"timestamp":1770219900588,"preClose":23.35,"halted":0,"volume":5121089,"delay":0,"changeRate":-0.012205567451820134,"floatShares":220698554,"shares":244977000,"eps":-0.97803,"marketStatus":"Trading","change":-0.285,"latestTime":"02-04 10:45:01 EST","open":23.36,"high":23.37,"low":22.96,"amount":118757490.59020999,"amplitude":0.017559,"askPrice":23.07,"askSize":3300,"bidPrice":23.06,"bidSize":2746,"shortable":3,"etf":0,"ttmEps":-0.97803,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1770238800000},"marketStatusCode":2,"adr":0,"listingDate":1721793600000,"exchange":"NASDAQ","adjPreClose":23.35,"preHourTrading":{"tag":"盘前","latestPrice":23.37,"preClose":23.35,"latestTime":"09:29 EST","volume":907,"amount":21195.691163,"timestamp":1770215399999,"change":0.02,"changeRate":0.000857,"amplitude":0.000857},"postHourTrading":{"tag":"盘后","latestPrice":23.33,"preClose":23.35,"latestTime":"17:58 EST","volume":119755,"amount":2796270.45,"timestamp":1770159538481,"change":-0.02,"changeRate":-0.000857,"amplitude":0.000857},"volumeRatio":3.987323,"impliedVol":0.1279,"impliedVolPercentile":0.0398},"requestUrl":"/m/hq/s/OS/wiki","defaultTab":"wiki","newsList":[{"id":"2608369855","title":"FTSE 100 touches record high, BoE policy in focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2608369855","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608369855?lang=en_us&edition=fundamental","pubTime":"2026-02-04 20:15","pubTimestamp":1770207326,"startTime":"0","endTime":"0","summary":"FTSE 100 touches record high, BoE policy in focusFor a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news windowFTSE 100 up 1.4% and FTSE 250 up 0.6%Energy stocks rise on higher crude amid U.S.-Iran tensionsSoftware, tech stocks still under pressureInvestors await BoE policy decision on Thursday","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nL6N3Z00N8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1829250122.USD","SG9999014906.USD","LU0823417737.USD","LU0997586432.USD","LU0550127509.SGD","LU2539964713.USD","LU0557290698.USD","LU0887340254.USD","LU1481011671.HKD","LU1732800096.USD","LU1934455277.USD","LU2210150020.SGD","SG9999014898.SGD","LU1037948541.HKD","LU0795875169.SGD","LU0827878280.USD","LU1732799900.SGD","IE0004091025.USD","LU1196032939.SGD","HGT.UK","LU2401740654.USD","LU1920062954.HKD","LU0965509010.AUD","OS","LU0965508806.USD","LU2279689827.SGD","REL.UK","LU1674673428.USD","LU0950375773.USD","LU1291149836.SGD","LU0047473722.EUR","LU1815333072.USD","LU0949170772.SGD","LU0957791311.USD","LU2095319765.USD","LU0963555726.SGD","LU0757428197.USD","LU0969580561.USD","LU1003077747.HKD","LU1104425308.USD","LU1037948897.HKD","IE00BKPKM643.USD","LU1481600234.SGD","LU1934455194.USD","LU1791806182.HKD","LU1599440770.SGD","LU1778281490.HKD","LU1481599808.USD","LU2506952097.USD","LU1989773731.SGD"],"gpt_icon":0},{"id":"2608182658","title":"OneStream transferred with Neutral rating at Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2608182658","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608182658?lang=en_us&edition=fundamental","pubTime":"2026-02-03 05:30","pubTimestamp":1770067842,"startTime":"0","endTime":"0","summary":"Piper Sandler kept a Neutral rating on OneStream (OS) with a $24 price target following a transfer of coverage. The firm downgraded three names and...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/onestream-transferred-with-neutral-rating-at-piper-sandler-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/onestream-transferred-with-neutral-rating-at-piper-sandler-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OS","BK4097"],"gpt_icon":0},{"id":"2607021562","title":"OneStream Inc. to Release Fourth Quarter and Full-Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2607021562","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607021562?lang=en_us&edition=fundamental","pubTime":"2026-01-31 05:05","pubTimestamp":1769807143,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OneStream Inc. published the original content used to generate this news brief via PR Newswire  on January 30, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nNDL5PLbZ4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4097","OS"],"gpt_icon":0},{"id":"2607115705","title":"Interim Results for the six months ended 31 October 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2607115705","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607115705?lang=en_us&edition=fundamental","pubTime":"2026-01-29 15:00","pubTimestamp":1769670000,"startTime":"0","endTime":"0","summary":"OXFORD, United Kingdom, Jan.  29, 2026  (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBodyand Moditopeactive immunotherapies to treat cancer, today announces a business","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/29/3228196/0/en/Interim-Results-for-the-six-months-ended-31-October-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B45NX917.SGD","LU0690374615.EUR","BK4142","BK4585","LU0690374961.EUR","IND","IE00B95QR487.USD","GB00B4LPDJ14.GBP","OS","BK4097","GB00B4QBRK32.GBP","RCC","BK4156","MAR","BK4195","BK4588","EMA","BK4211","IE00B0T0GQ85.USD","LU1718418525.SGD","IE00B1G9WX41.USD","LU2404859667.USD","LU2404859741.USD","BK4081","PFS","IE00BD0PCF45.HKD"],"gpt_icon":0},{"id":"2605417097","title":"Tech Buyouts Are Coming. 6 Stocks That Can Benefit. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2605417097","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605417097?lang=en_us&edition=fundamental","pubTime":"2026-01-23 05:31","pubTimestamp":1769117460,"startTime":"0","endTime":"0","summary":"A batch of technology companies appear to be candidates to attract buyout offers. Investors could profit when deals are announced.Suitors can now buy software companies with smaller market capitalizations at lower prices than several months ago. There's no shortage of such names: The $1.8 billion C3.ai, whose stock has fallen 90% since the company went public in 2022, is one example. The $2.6 billion nCino, down 69% since its 2020 initial public offering, is another.Those stocks are suffering because companies such as OpenAI and Anthropic are creating artificial-intelligence models that could steal the lunches of many niche software providers. The little guys may not have the scale, financing, expertise, or intellectual property to sustainably compete with the heavy-hitters.The resulting drop in the small-cap stocks opens the door to potential deals. Private-equity firm Thoma Bravo's founder Orlando Bravo told the Financial Times this week that he sees clear buying opportunities in sma","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1720051108.HKD","BK4535","LU2264538146.SGD","BK4528","LU1988902786.USD","LU1064131342.USD","BK4613","BK4023","BK4548","BK4097","BK4607","OS","GTLB","LU2357305700.SGD","BK4585","LU2148611432.USD","BK4551","LU1720051017.SGD","LU1548497426.USD","BK4588","DDOG","NCNO","BK4561","LU2286300806.USD"],"gpt_icon":0},{"id":"2605148149","title":"MEDIA-Goldman, Blue Owl eye $3 billion private loan for OneStream deal - Bloomberg News","url":"https://stock-news.laohu8.com/highlight/detail?id=2605148149","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605148149?lang=en_us&edition=fundamental","pubTime":"2026-01-22 01:03","pubTimestamp":1769015012,"startTime":"0","endTime":"0","summary":"MEDIA-Goldman, Blue Owl eye $3 billion private loan for OneStream deal - Bloomberg News-- Source link: https://tinyurl.com/bcx926hj-- Note: Reuters has not verified this story and does not vouch for its accuracy((globalnewsmonitoring@thomsonreuters.com))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nL6N3YM14D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443622.USD","LU1868836757.USD","IE00BLSP4452.SGD","IE00BBT3K403.USD","OWL","IE0034235188.USD","LU1894683264.USD","LU2237443549.SGD","IE0004091025.USD","LU1868836591.USD","BK4552","IE0004086264.USD","LU0742534661.SGD","LU2471134523.USD","BK4585","LU2237443895.HKD","IE00BFXG1179.USD","LU0251142724.SGD","LU1868836914.USD","LU2265009873.SGD","BK4127","LU1804176565.USD","GS","LU0048573561.USD","LU2471134952.CNY","LU2237438978.USD","LU2471134879.HKD","IE0002270589.USD","LU1868837136.USD","IE00B19Z3B42.SGD","LU0345770308.USD","LU0096364046.USD","LU1791807156.HKD","LU0061475181.USD","BK4135","LU2237443978.SGD","OS","LU2237443465.HKD","LU1868837300.USD","LU1894683348.USD","LU0106831901.USD","IE00BSNM7G36.USD","LU2750360641.GBP","LU2471134796.USD","BK4504","BK4550","IE00BN8TJ469.HKD","BK4097","BK4533","LU0345770993.USD"],"gpt_icon":0},{"id":"2605143278","title":"Genmab Lymphoma Study Misses Key Target, Analyst Still Sees Upside","url":"https://stock-news.laohu8.com/highlight/detail?id=2605143278","media":"Benzinga_recent_news","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605143278?lang=en_us&edition=fundamental","pubTime":"2026-01-21 02:36","pubTimestamp":1768934160,"startTime":"0","endTime":"0","summary":"Genmab shared Phase 3 trial results for epcoritamab in lymphoma, missing overall survival but improving disease control, as analyst weighs approval risks and future trial data.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/20/Cancer---Heart-Shape-To-Represent-Medica.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/20/Cancer---Heart-Shape-To-Represent-Medica.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/large-cap/26/01/50016085/genmab-lymphoma-study-misses-key-target-analyst-still-sees-upside","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/large-cap/26/01/50016085/genmab-lymphoma-study-misses-key-target-analyst-still-sees-upside","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU0289739343.SGD","LU0820561818.USD","LU0820561909.HKD","LU0058720904.USD","IE0004445239.USD","LU0256863811.USD","LU1228905037.USD","OS","IE0002141913.USD","IE00B2B36J28.USD","LU1291159041.SGD","IE00BSNM7G36.USD","LU0708994859.HKD","LU1023059063.AUD","LU1061106388.HKD","LU0211327993.USD","LU1496350171.SGD","LU1934455194.USD","IE00BFTCPJ56.SGD","LU0114720955.EUR","LU0472753341.HKD","IE0009355771.USD","BR","LU1093756168.USD","ABBV","LU0795875169.SGD","IE00B3PB1722.GBP","LU0882574055.USD","BK4588","LU0390134368.USD","LU1003077747.HKD","BK4581","LU0211328371.USD","IE00BN8TJ469.HKD","LU0689626769.HKD","LU0738911758.USD","LU2089283258.USD","LU2023251221.USD","GMAB","LU0057025933.USD","IE00B42XCP33.USD","IE00BBT3K403.USD","IE00B19Z3B42.SGD","LU1430594728.SGD","IE00BJT1NW94.SGD","LU0545562505.USD","SG9999011175.SGD","LU0965509283.SGD","PFS","IE00BGHQF631.EUR"],"gpt_icon":0},{"id":"2604190551","title":"Avacta Announces Year-end Trading Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2604190551","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604190551?lang=en_us&edition=fundamental","pubTime":"2026-01-20 20:00","pubTimestamp":1768910400,"startTime":"0","endTime":"0","summary":"LONDON and PHILADELPHIA, Jan.  20, 2026  (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a clinical stage biopharmaceutical company developing pre|CISION,a tumor-activated oncology delivery platf","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/20/3221535/0/en/Avacta-Announces-Year-end-Trading-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4565","OS","LU0359201612.USD","IE00BYQNZ168.SGD","IP","BK4535","BK4509","LU1481600234.SGD","BK4108","LU2463526074.USD","BK4571","LU0828238088.HKD","BK4552","LU0509642566.USD","LU0456842615.SGD","BK4097","IE00B12V2V27.USD","BK4548","BK4563","LU1481599808.USD","BK4531","LU1169589451.USD","BK4526","BK4585","IE00B3T34201.USD","LU0359202008.SGD","01698","BK4136","LU0269904917.USD","LU1487256676.USD","IE00BYTNYN87.SGD","BK4588","LU1169590202.USD","SG9999011746.SGD","LU1023057109.AUD","TME","LU2039709279.SGD"],"gpt_icon":0},{"id":"2604796913","title":"Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2604796913","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604796913?lang=en_us&edition=fundamental","pubTime":"2026-01-17 02:30","pubTimestamp":1768588200,"startTime":"0","endTime":"0","summary":"Company Announcement  Based on the topline results from the EPCORE DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss next steps COPENHAGEN, Denmark; January 16, 2026 – Genmab ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/16/3220513/0/en/Genmab-Announces-Topline-Results-for-Epcoritamab-DuoBody-CD3xCD20-from-Phase-3-EPCORE-DLBCL-1-Trial-in-Patients-with-Relapsed-Refractory-Diffuse-Large-B-cell-Lymphoma-DLBCL.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4106","BK4226","BK4548","LU0390134368.USD","IE0034235188.USD","BK4195","BK4211","PFS","BR","LU1228905037.USD","BK4097","BK4588","IE0009354923.USD","LU1228905540.USD","BK4585","OS","LU0545562505.USD"],"gpt_icon":0},{"id":"2603475993","title":"JPMorgan Downgrades Onestream to Underweight From Neutral, Adjusts Price Target to $24 From $23","url":"https://stock-news.laohu8.com/highlight/detail?id=2603475993","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603475993?lang=en_us&edition=fundamental","pubTime":"2026-01-16 20:21","pubTimestamp":1768566118,"startTime":"0","endTime":"0","summary":"Onestream (OS) has an average rating of hold and mean price target of $24.13, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OS"],"gpt_icon":0},{"id":"2603962028","title":"OneStream downgraded to Underweight from Neutral at JPMorgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2603962028","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603962028?lang=en_us&edition=fundamental","pubTime":"2026-01-16 18:35","pubTimestamp":1768559743,"startTime":"0","endTime":"0","summary":"JPMorgan downgraded OneStream (OS) to Underweight from Neutral with a price target of $24, up from $23, citing the pending takeover by Hg. Publishe...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/onestream-downgraded-to-underweight-from-neutral-at-jpmorgan-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/onestream-downgraded-to-underweight-from-neutral-at-jpmorgan-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0211328371.USD","LU2023250330.USD","BK4504","BK4207","LU0215105999.USD","LU0820562030.AUD","LU1119994496.HKD","IE00B1XK9C88.USD","LU2054465674.USD","LU1162221912.USD","LU2211815571.USD","LU2237443978.SGD","LU0149725797.USD","LU0976567544.SGD","OS","IE0034235295.USD","LU0943347566.SGD","LU1551013342.USD","LU0868494708.USD","LU2505996681.GBP","LU1668664300.SGD","LU0820561818.USD","LU0267386448.USD","IE00BLSP4239.USD","LU0211326839.USD","IE00BN8TJ469.HKD","LU1894683264.USD","LU2023250504.SGD","SG9999002232.USD","LU0882574139.USD","LU0234572021.USD","LU2430703095.HKD","IE00BBT3K403.USD","LU0787776722.HKD","LU2264538146.SGD","IE00B775SV38.USD","LU2357305700.SGD","LU2237443895.HKD","IE00BYXW3230.USD","LU1366192091.USD","IE00BWXC8680.SGD","LU0320765646.SGD","LU0964807845.USD","BK4097","LU1084165304.USD","LU0251132253.USD","IE00BFXG1179.USD","LU1496350171.SGD","LU2236285917.USD","LU0208291251.USD"],"gpt_icon":0},{"id":"2603987374","title":"Johnson & Johnson Drug Slows Blood Cancer, Extends Survival In Pretreated Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2603987374","media":"Benzinga_recent_news","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603987374?lang=en_us&edition=fundamental","pubTime":"2026-01-16 01:36","pubTimestamp":1768498560,"startTime":"0","endTime":"0","summary":"Johnson & Johnson reports Phase 3 results showing Tecvayli reduced disease progression and deaths in multiple myeloma patients, beating standard treatments with manageable side effects.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/15/Exterior-Shot-Of-The-Johnson-Johnson-Cor.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/15/Exterior-Shot-Of-The-Johnson-Johnson-Cor.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/large-cap/26/01/49944767/johnson-johnson-drug-slows-blood-cancer-extends-survival-in-pretreated-patients","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/large-cap/26/01/49944767/johnson-johnson-drug-slows-blood-cancer-extends-survival-in-pretreated-patients","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU2430703095.HKD","LU0795875086.SGD","PFS","LU1280957306.USD","LU1244550494.USD","LU2129689431.USD","LU1057294990.SGD","LU2129689514.USD","LU1894683264.USD","IE00BJJMRZ35.SGD","LU2089984988.USD","IE00BVYPNV92.GBP","BK4097","LU1496350502.SGD","LU2471134796.USD","IE00BGHQF631.EUR","LU1221951129.SGD","LU1244550577.SGD","LU0640476718.USD","IE0034235303.USD","BK4588","IE00BLSP4452.SGD","LU2468319806.SGD","LU0432979614.USD","IE0002141913.USD","IE00BKVL7J92.USD","IE00BFTCPJ56.SGD","LU0345770993.USD","LU1023059063.AUD","LU1929549753.HKD","IE00BSNM7G36.USD","OS","IE00B19Z3B42.SGD","BK4559","IE00BBT3K403.USD","LU2347655156.SGD","LU0787776722.HKD","LU0320765646.SGD","IE0009355771.USD","BK4007","LU1585245621.USD","JNJ","IE00BVYPNW00.USD","LU2133065610.SGD","SG9999002224.SGD","SG9999001440.SGD","IE00BDGV0183.EUR","BK4581","IE000M9KFDE8.USD","LU0234572021.USD"],"gpt_icon":0},{"id":"2603071600","title":"EXCLUSIVE: GT Biopharma Plans 2026 Trial For New Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2603071600","media":"Benzinga_recent_news","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603071600?lang=en_us&edition=fundamental","pubTime":"2026-01-15 21:01","pubTimestamp":1768482060,"startTime":"0","endTime":"0","summary":"GT Biopharma submitted an IND application for GTB-5550 TriKE for solid tumors. Phase 1 trial planned for 2026.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/15/cancer.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/15/cancer.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/fda/26/01/49931692/exclusive-gt-biopharma-plans-2026-trial-for-new-cancer-treatment","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/fda/26/01/49931692/exclusive-gt-biopharma-plans-2026-trial-for-new-cancer-treatment","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU2413666699.HKD","GTBP","PFS","BK4139","BK4567","LU1721428933.USD","BK4211","MTD","BK4121","BK4548","IE00BFXG0V08.USD","BK4097","BK4533","IE00BYQQ9H92.USD","IE00B5TLWC47.USD","OS","BK4585","BK4119","IND","LU2211817866.USD","LU1093756325.SGD","LU2413666426.HKD","BK4195","LU0347712357.USD","GT","BK4588","LU1093756168.USD"],"gpt_icon":0},{"id":"2603070006","title":"OneStream downgraded to Neutral from Outperform at BNP Paribas","url":"https://stock-news.laohu8.com/highlight/detail?id=2603070006","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603070006?lang=en_us&edition=fundamental","pubTime":"2026-01-15 20:50","pubTimestamp":1768481441,"startTime":"0","endTime":"0","summary":"BNP Paribas downgraded OneStream (OS) to Neutral from Outperform with a $24 price target after the company announced that it has entered into an ag...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/onestream-downgraded-to-neutral-from-outperform-at-bnp-paribas-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/onestream-downgraded-to-neutral-from-outperform-at-bnp-paribas-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OS","BK4097"],"gpt_icon":0},{"id":"2602851062","title":"Press Release: Rigel Provides Business Update and 2026 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2602851062","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602851062?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:05","pubTimestamp":1768223100,"startTime":"0","endTime":"0","summary":"-- Preliminary fourth quarter 2025 total revenue of approximately $69.8. million, including net product sales of $65.4 million and contract. RBC-TI was achieved by 33%  of evaluable transfusion dependent. $275 to $290 million, including net product sales of $255 to $265 million,\"2025 was an excellent year for Rigel, marked by strong commercial execution with record net product sales; significant financial progress, including continued profitability and generation of $77 million in cash; and meaningful clinical advancement of R289 in lower-risk MDS, where we shared encouraging Phase 1b data,\" said Raul Rodriguez, Rigel's president and CEO. \"In 2026, we plan to continue to execute across all areas of the business -- driving sustained commercial performance, supporting our expanding clinical programs with a solid financial foundation, delivering preliminary results from the dose expansion phase of our R289 study and continuing to explore opportunities to add new products to our portfolio.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK4109","BK4139","BK4022","BK4211","ORR","LU2463526074.USD","OS","RIGL","ASH","R","BK4097","HTB"],"gpt_icon":0},{"id":"2602515003","title":"Press Release: Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602515003","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602515003?lang=en_us&edition=fundamental","pubTime":"2026-01-12 18:37","pubTimestamp":1768214220,"startTime":"0","endTime":"0","summary":"-- Cabozantinib franchise achieves approximately $2.123 billion in preliminary U.S. net product revenues for fiscal year 2025 --. -- Fiscal year 2026 net product revenues guidance of $2.325 billion - $2.425 billion --. -- Presentation and webcast at J.P. Morgan 2026 Healthcare Conference tomorrow, Monday, January 12 at 5:15 p.m. PT / 8:15 p.m. ET --. Exelixis, Inc.  today announced its preliminary unaudited financial results for the fiscal year 2025, provided financial guidance for fiscal year 2026 and delivered an update on its business. Exelixis anticipates 2026 will be a significant year of clinical, regulatory and commercial progress as the company grows its current cabozantinib business, works toward building a potential second commercial franchise with zanzalintinib and moves its earlier stage pipeline forward. As outlined at its December 2025 R&D Day, the company seeks to leverage its diverse pipeline and key clinical collaborations to build next-generation oncology franchises t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4560","PFS","R","BK4139","LU2065171402.SGD","BK4554","ORR","BK4211","BK4232","LU0266512127.USD","BK4613","BK4116","BK4548","BK4097","LU2065170008.USD","BK4607","OS","BK4213","CRC","BK4022","BK4585","LU2065171311.SGD","RCC","EXEL","LU2065169927.USD","BK4195","BK4588","BK4532","NET","LU2286300806.USD","LU0456854461.SGD"],"gpt_icon":0},{"id":"2602634505","title":"Zymeworks Outlines Strategic Priorities and Outlook for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602634505","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602634505?lang=en_us&edition=fundamental","pubTime":"2026-01-12 07:00","pubTimestamp":1768172400,"startTime":"0","endTime":"0","summary":"Positive Phase 3 HERIZON-GEA-01 results for Ziihera (zanidatamab-hrii) in first-line HER2-positive (HER2+)gastroesophageal adenocarcinoma (GEA) presented at ASCO GI Up to $440.0 million in milestone p","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/11/3216504/0/en/Zymeworks-Outlines-Strategic-Priorities-and-Outlook-for-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0330918003.SGD","BK4195","PT","LU0788108826.HKD","BK4080","LU0498741890.SGD","BK4231","LU0300736062.USD","LU1430597077.USD","BK4211","LU0345780281.USD","LU0345781412.USD","LU0498741114.HKD","SG9999001143.SGD","SG9999002521.SGD","LU0612318971.USD","BK4161","LU0345780950.USD","LU0055631609.USD","B","JF","LU0630314457.HKD","LU0368265764.SGD","LU1023059493.AUD","LU0075056555.USD","PFS","LU0788109121.HKD","LU0496367417.USD","LU0724618789.USD","BK4097","BK4017","LU0612318385.USD","ADC","IND","BK4166","OS","LU0345780521.USD","LU0654597011.USD","LU0300736492.USD"],"gpt_icon":0},{"id":"2602024603","title":"OneStream Inc. Chief Accounting Officer Pamela McIntyre Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2602024603","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602024603?lang=en_us&edition=fundamental","pubTime":"2026-01-10 07:19","pubTimestamp":1768000747,"startTime":"0","endTime":"0","summary":"Pamela McIntyre, Chief Accounting Officer of OneStream Inc., reported a disposal of common shares of OneStream Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OneStream Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 09, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDL29n82W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"OneStream Inc. Chief Accounting Officer Pamela McIntyre Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OS","BK4097"],"gpt_icon":0},{"id":"2602302197","title":"Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2602302197","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602302197?lang=en_us&edition=fundamental","pubTime":"2026-01-10 07:01","pubTimestamp":1767999660,"startTime":"0","endTime":"0","summary":"- Rapidly transforming into a leading global biopharma companyCOPENHAGEN, Denmark, Jan.  09, 2026  (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided a business and strategic roadma","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/09/3216381/0/en/Ascendis-Pharma-Provides-Business-and-Strategic-Roadmap-Update-at-44th-Annual-J-P-Morgan-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4125","LU1074936037.SGD","LU1720051108.HKD","LU1989772840.SGD","LU2347655156.SGD","LU2133065610.SGD","BK4081","LU0528227936.USD","MAA","IE00BZ1G4Q59.USD","LU0557290698.USD","LU2111349929.HKD","LU1244550221.USD","EMA","LU0795875169.SGD","SGA","LU0795875086.SGD","LU0971096721.USD","LU0234570918.USD","LU1791710582.SGD","LU1244550494.USD","LU0098860793.USD","LU1989772923.USD","BK4007","OS","PROC","BK4585","BK4137","LABU","LU1791710400.SGD","LU0912757837.SGD","BK4215","XLV","BK4534","BK4581","XBI","BK4127","LU2023251221.USD","HCSG","LU0314104364.USD","LU2028103732.USD","LU1244550577.SGD","LU0106261372.USD","LU1548497426.USD","BK4588","LU0029874061.USD","LU1732800096.USD","LU0882574139.USD","LU2089283258.USD","BK4504"],"gpt_icon":0},{"id":"2602139483","title":"Cellectis Announces 2026 Strategy and Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2602139483","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602139483?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:30","pubTimestamp":1767907800,"startTime":"0","endTime":"0","summary":"NEW YORK, Jan.  08, 2026  (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to de","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/08/3215815/0/en/Cellectis-Announces-2026-Strategy-and-Catalysts.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASH","BK4505","CLLS","ORR","BK4097","LU2463526074.USD","BK4139","TIL","BK4109","OS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.onestream.com","stockEarnings":[{"period":"1week","weight":-0.0139},{"period":"1month","weight":0.3177},{"period":"3month","weight":0.1611},{"period":"6month","weight":0.0509},{"period":"1year","weight":-0.1831},{"period":"ytd","weight":0.2704}],"compareEarnings":[{"period":"1week","weight":-0.0086},{"period":"1month","weight":0.0093},{"period":"3month","weight":0.0176},{"period":"6month","weight":0.0906},{"period":"1year","weight":0.1535},{"period":"ytd","weight":0.0112}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"exchange":"NASDAQ","name":"OneStream, Inc.","nameEN":"OneStream, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"OneStream, Inc.(OS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest OneStream, Inc.(OS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"OneStream, Inc.,OS,OneStream, Inc.股票,OneStream, Inc.股票老虎,OneStream, Inc.股票老虎国际,OneStream, Inc.行情,OneStream, Inc.股票行情,OneStream, Inc.股价,OneStream, Inc.股市,OneStream, Inc.股票价格,OneStream, Inc.股票交易,OneStream, Inc.股票购买,OneStream, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"OneStream, Inc.(OS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest OneStream, Inc.(OS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction